PharmaMar and Eczac?bas? Sign a Licensing Agreement for Aplidin® in Turkey

Madrid (ots/PRNewswire) -

PharmaMar (MCE:PHM) has announced today a licensing agreement with
Eczac?bas? Group to commercialize the marine-derived anticancer drug
Aplidin® (plitidepsin) in Turkey. Under the terms of the agreement,
PharmaMar will receive an upfront payment as well as development
milestones related to the health approval procedure of Aplidin® in
this country. PharmaMar will retain exclusive production rights and
will supply the finished product to Eczac?bas? for commercial use.

(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

Aplidin® is PharmaMar´s second most advanced anticancer drug
currently under development for the treatment of multiple myeloma and
angioimmunoblastic T-cell lymphoma. The Company announced in March
2016 that plitidepsin has shown positive results in a pivotal Phase
III clinical trial (ADMYRE) for multiple myeloma[i] and in September
2016, PharmaMar presented to the European Medicines Agency (EMA) the
submission of the Marketing Authorization Application (MAA) for this
drug in combination with dexamethasone for the treatment of
relapsed/refractory multiple myeloma (MM)[ii] .

"The partnership with Eczac?bas? will help in the
commercialization in Turkey of plitidepsin, developed to tackle
hematologic cancer. We are looking forward to working with one of the
leading Health Care companies in this country", said Luis Mora,
Managing Director of PharmaMar´s Oncology Business Unit. "We are
firmly committed to advancing in the development of innovative
oncology therapies", he added.

Atalay Gümrah, CEO and President of the Eczac?bas? Group, stated
that "the agreement between PharmaMar and Eczac?bas? Pharmaceuticals
Marketing (EIP) offered a major advance for healthcare in Turkey, as
Aplidin® represented the latest innovation in cancer treatment". Elif
Çelik, Executive Vice President of the Eczac?bas? Healthcare
Division, noted that "the agreement ensured that multiple myeloma
patients in Turkey would have access to the most innovative treatment
at the same time as patients in other EU countries". She added that
"the two parties hoped to extend the partnership to innovative
products in other treatment areas as well".

i. https://www.pharmamar.com/2016/03/31/aplidin-shows-positive-res
ults-in-pivotal-phase-iii-clinical-trial-for-multiple-myeloma/

ii. http://www.pharmamar.com/wp-content/uploads/2016/09/PharmaMar-
submits-MAA-to-EMA-for-Aplidin.pdf

CONTACT: Media Relations (+34-638-79-62-15) and Investor Relations
(+34-914444500)

ots Originaltext: PharmaMar
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: PharmaMar, übermittelt durch news aktuell